company background image
VIRP

VirbacENXTPA:VIRP Stock Report

Market Cap

€3.3b

7D

6.7%

1Y

90.1%

Updated

25 Oct, 2021

Data

Company Financials +
VIRP fundamental analysis
Snowflake Score
Valuation1/6
Future Growth1/6
Past Performance5/6
Financial Health6/6
Dividends0/6

VIRP Overview

Virbac SA manufactures and sells pharmaceutical, biological, nutritional, and diagnostic products for companion and food-producing animals in France, Europe, Latin America, North America, the Asia Pacific, and the Middle East and Africa.

Virbac Competitors

Sanofi

ENXTPA:SAN

€106.8b

Vetoquinol

ENXTPA:VETO

€1.7b

Eli Lilly

NYSE:LLY

US$221.0b

Merck

NYSE:MRK

US$205.4b

Price History & Performance

Summary of all time highs, changes and price drops for Virbac
Historical stock prices
Current Share Price€411.50
52 Week High€199.00
52 Week Low€397.50
Beta0.89
1 Month Change7.16%
3 Month Change24.32%
1 Year Change90.07%
3 Year Change189.79%
5 Year Change183.79%
Change since IPO3,248.79%

Recent News & Updates

Oct 12
Is Virbac (EPA:VIRP) Using Too Much Debt?

Is Virbac (EPA:VIRP) Using Too Much Debt?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

Sep 26
Here's Why I Think Virbac (EPA:VIRP) Might Deserve Your Attention Today

Here's Why I Think Virbac (EPA:VIRP) Might Deserve Your Attention Today

For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...

Shareholder Returns

VIRPFR PharmaceuticalsFR Market
7D6.7%1.5%0.7%
1Y90.1%4.8%35.2%

Return vs Industry: VIRP exceeded the French Pharmaceuticals industry which returned 4.8% over the past year.

Return vs Market: VIRP exceeded the French Market which returned 35.2% over the past year.

Price Volatility

Is VIRP's price volatile compared to industry and market?
VIRP volatility
VIRP Beta0.89
Industry Beta0.47
Market Beta1

Stable Share Price: VIRP is not significantly more volatile than the rest of French stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: VIRP's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19684,907Sebastien Huronhttps://corporate.virbac.com

Virbac SA manufactures and sells pharmaceutical, biological, nutritional, and diagnostic products for companion and food-producing animals in France, Europe, Latin America, North America, the Asia Pacific, and the Middle East and Africa. The company offers a range of vaccines, dental hygiene, reproduction, dermatology, parasiticides, diagnostic, antibiotics, and aquaculture products; and veterinary medicines for anesthesia, geriatrics, behavior, and injectable micronutrients, as well as petfood and electronic identification. Virbac SA was founded in 1968 and is headquartered in Carros, France.

Virbac Fundamentals Summary

How do Virbac's earnings and revenue compare to its market cap?
VIRP fundamental statistics
Market Cap€3.25b
Earnings (TTM)€163.02m
Revenue (TTM)€985.30m

21.3x

P/E Ratio

3.5x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
VIRP income statement (TTM)
Revenue€985.30m
Cost of Revenue€333.83m
Gross Profit€651.48m
Expenses€488.46m
Earnings€163.02m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)19.31
Gross Margin66.12%
Net Profit Margin16.54%
Debt/Equity Ratio12.4%

How did VIRP perform over the long term?

See historical performance and comparison

Dividends

0.2%

Current Dividend Yield

4%

Payout Ratio

Valuation

Is Virbac undervalued compared to its fair value and its price relative to the market?

21.31x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: VIRP (€385) is trading below our estimate of fair value (€385.63)

Significantly Below Fair Value: VIRP is trading below fair value, but not by a significant amount.


Price To Earnings Ratio

PE vs Industry: VIRP's PE Ratio (19.9x) is in line with the French Pharmaceuticals industry average.

PE vs Market: VIRP is poor value based on its PE Ratio (19.9x) compared to the French market (19.5x).


Price to Earnings Growth Ratio

PEG Ratio: VIRP is poor value based on its PEG Ratio (7x)


Price to Book Ratio

PB vs Industry: VIRP is overvalued based on its PB Ratio (4.6x) compared to the FR Pharmaceuticals industry average (3.6x).


Future Growth

How is Virbac forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?

6.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: VIRP's forecast earnings growth (2.8% per year) is above the savings rate (0.3%).

Earnings vs Market: VIRP's earnings (2.8% per year) are forecast to grow slower than the French market (12.3% per year).

High Growth Earnings: VIRP's earnings are forecast to grow, but not significantly.

Revenue vs Market: VIRP's revenue (4.7% per year) is forecast to grow slower than the French market (6.2% per year).

High Growth Revenue: VIRP's revenue (4.7% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: VIRP's Return on Equity is forecast to be low in 3 years time (13.7%).


Past Performance

How has Virbac performed over the past 5 years?

47.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: VIRP has a large one-off gain of €66.9M impacting its June 30 2021 financial results.

Growing Profit Margin: VIRP's current net profit margins (16.5%) are higher than last year (7.6%).


Past Earnings Growth Analysis

Earnings Trend: VIRP's earnings have grown significantly by 47.8% per year over the past 5 years.

Accelerating Growth: VIRP's earnings growth over the past year (125.6%) exceeds its 5-year average (47.8% per year).

Earnings vs Industry: VIRP earnings growth over the past year (125.6%) exceeded the Pharmaceuticals industry 10.2%.


Return on Equity

High ROE: VIRP's Return on Equity (22.8%) is considered high.


Financial Health

How is Virbac's financial position?


Financial Position Analysis

Short Term Liabilities: VIRP's short term assets (€638.7M) exceed its short term liabilities (€356.2M).

Long Term Liabilities: VIRP's short term assets (€638.7M) exceed its long term liabilities (€106.5M).


Debt to Equity History and Analysis

Debt Level: VIRP's debt to equity ratio (12.4%) is considered satisfactory.

Reducing Debt: VIRP's debt to equity ratio has reduced from 134.6% to 12.4% over the past 5 years.

Debt Coverage: VIRP's debt is well covered by operating cash flow (128.4%).

Interest Coverage: VIRP's interest payments on its debt are well covered by EBIT (26.1x coverage).


Balance Sheet


Dividend

What is Virbac current dividend yield, its reliability and sustainability?

0.18%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: VIRP's dividend (0.19%) isn’t notable compared to the bottom 25% of dividend payers in the French market (1.32%).

High Dividend: VIRP's dividend (0.19%) is low compared to the top 25% of dividend payers in the French market (3.93%).


Stability and Growth of Payments

Stable Dividend: VIRP is not paying a notable dividend for the French market, therefore no need to check if payments are stable.

Growing Dividend: VIRP is not paying a notable dividend for the French market, therefore no need to check if payments are increasing.


Current Payout to Shareholders

Dividend Coverage: VIRP is not paying a notable dividend for the French market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of VIRP's dividend in 3 years as they are not forecast to pay a notable one for the French market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.3yrs

Average management tenure


CEO

Sebastien Huron (50 yo)

3.83yrs

Tenure

€579,838

Compensation

Mr. Sebastien Huron has been Chairman of Executive Board at Virbac SA since December 20, 2017. He served as the Head of Global Business Operations at Virbac SA since 2014 and has been its Member of Executi...


CEO Compensation Analysis

Compensation vs Market: Sebastien's total compensation ($USD674.47K) is below average for companies of similar size in the French market ($USD1.63M).

Compensation vs Earnings: Sebastien's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: VIRP's management team is considered experienced (2.3 years average tenure).


Board Members

Experienced Board: VIRP's board of directors are considered experienced (4.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Virbac SA's employee growth, exchange listings and data sources


Key Information

  • Name: Virbac SA
  • Ticker: VIRP
  • Exchange: ENXTPA
  • Founded: 1968
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: €3.251b
  • Shares outstanding: 8.44m
  • Website: https://corporate.virbac.com

Number of Employees


Location

  • Virbac SA
  • 13e rue LID - BP 27
  • Cedex
  • Carros
  • Provence-Alpes-Côte d'Azur
  • 6511
  • France

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/25 18:01
End of Day Share Price2021/10/25 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.